Lupin Limited today announced that its alliance partner Caplin Steriles Limited has received final approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection, via an exchange filing.
The approved dosages are 10mg/mL in 5 mL and 10 mL Multi-Dose Vials, to market a generic version of Zemuron Bromide Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc.
Rocuronium Bromide Injection (RLD: Zemuron) had an annual sale of approximately USD 53 million in the U.S. (IQVIA MAT December 2022).
Read Also
Lupin’s alliance partner Caplin receives USFDA approval for Thiamine Hydrochloride Injection
Ravindra Chavan Files Nomination For BJP Maharashtra President Post
Uddhav Thackeray Claims Victory As Maharashtra Withdraws Hindi GRs Amidst Protest Threat
Navi Mumbai Tragedy: Speeding Vehicle Kills Golden Jackal Near DPS Flamingo Lake In Nerul; Environmentalists Demand Action
Punjab Police Bust International Drug Racket; 60 Kg Heroin Seized, 9 Held
